X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2022/07/18/2480937/37424/en/Nabriva-Therapeutics-Expands-XENLETA-lefamulin-Presence-with-Exclusive-Agreement-with-Er-Kim-Pharmaceuticals.html
https://www.globenewswire.com/news-release/2022/04/11/2420431/37424/en/Nabriva-Therapeutics-Announces-First-Patient-Enrolled-in-Phase-1-Trial-of-XENLETA-lefamulin-in-Adult-Patients-with-Cystic-Fibrosis.html
https://www.globenewswire.com/news-release/2021/11/11/2332502/37424/en/Nabriva-Announces-Availability-of-XENLETA-lefamulin-in-a-10-Count-Oral-Pack.html
https://www.globenewswire.com/news-release/2021/10/04/2308286/37424/en/Nabriva-Publishes-Data-Demonstrating-the-Potent-Anti-Inflammatory-Properties-of-XENLETA-lefamulin.html
https://www.globenewswire.com/news-release/2021/10/04/2308286/37424/en/Nabriva-Publishes-Data-Demonstrating-the-Potent-Anti-Inflammatory-Properties-of-XENLETA-lefamulin.html
https://www.globenewswire.com/news-release/2021/09/24/2302872/37424/en/Nabriva-Therapeutics-to-Present-Data-at-IDWeek-2021.html
https://seekingalpha.com/news/3737849-nabriva-shares-rise-after-xenleta-approval-in-taiwan
https://www.globenewswire.com/news-release/2020/07/28/2068781/0/en/NABRIVA-Receives-European-Approval-for-XENLETA-lefamulin-for-Treatment-of-Community-Acquired-Pneumonia-CAP.html
https://www.globenewswire.com/news-release/2020/07/23/2066452/0/en/Lefamulin-Demonstrates-Anti-Inflammatory-Activity-in-Pre-Clinical-Study.html#:~:text=The%20research%20findings%20reflect%20the,anti%2Dinflammatory%20activity%20of%20lefamulin.&text=Importantly%2C%20lefamulin%20demonstrated%20reductions%20in,at%20all%20lefamulin%20doses%20tested.
https://www.globenewswire.com/news-release/2020/07/16/2063622/0/en/XENLETA-lefamulin-Receives-Health-Canada-Approval-for-Treatment-of-Community-Acquired-Pneumonia.html
https://www.businesswire.com/news/home/20200706005015/en/WEP-Clinical-Partners-Nabriva-Therapeutics-Named-Patient
http://www.pharmatimes.com/news/new_vaccine_for_ebola_among_chmp_recommendations_1341219
https://www.globenewswire.com/news-release/2020/05/05/2027398/0/en/XENLETA-Lefamulin-Treatment-Results-in-a-Rapid-Time-to-Clinical-Response-in-Hospitalized-Patients-with-Community-Acquired-Bacterial-Pneumonia-CABP.html
https://markets.businessinsider.com/news/stocks/centers-for-medicare-medicaid-services-issues-product-specific-j-code-for-xenleta-1029079286
https://www.biospace.com/article/releases/nabriva-to-present-data-at-the-chest-annual-meeting-demonstrating-the-safety-and-efficacy-of-newly-fda-approved-xenleta-lefamulin-for-the-treatment-of-cabp-poster-sessions-to-highlight-pooled-results-from-the-pivo/?s=95
https://www.fiercepharma.com/marketing/nabriva-scores-fda-nod-for-novel-antibiotic-to-treat-bacterial-pneumonia
https://www.biospectrumasia.com/news/34/14272/fda-approves-new-antibiotic-to-treat-community-acquired-bacterial-pneumonia.html
https://health.economictimes.indiatimes.com/news/pharma/fda-approves-nabrivas-antibiotic-for-pneumonia/70749126
https://endpts.com/roivant-brings-pfizer-vets-azoulay-gulfo-into-its-c-suite-fludzinski-jumps-from-lilly-to-amidebios-helm/
Market Place
Share 
